Novavax Inc at Citi BioPharma Conference (Virtual) Transcript
Hi. My name is Mike Guba. I'm Citi's U.S. health care sector specialist. And today, I have the pleasure of welcoming Greg Glenn, Novavax' President of R&D; as well as John Trizzino, Executive Vice President and Chief Commercial Officer and Chief Business Officer for Novavax.
Greg, John, thank you very much for joining us.
Questions & Answers
Just to kick it off, right, I've been hopping right into it because it's been a long day for just about everyone, so I think we should just get straight to the content. So starting off at a high level, can you kind of give us a brief state of the union on where your COVID vaccine program stands as of now? Has there been any update since 2Q that you'd like to share to the market? And any kind of just broad, broad statements there to start.
Yes. So thanks, and thanks for having us, Mike. We're at a great place with our vaccine. We did a number of trials in vaccines. You do
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
